Article

Topical antibiotic treatment effective in preventing endophthalmitis

Salt Lake City-Topical antibiotic therapy before and after intraocular bacterial challenge in rabbits could prevent Staphylococcus epidermidis endophthalmitis from developing.

Prophylaxis with a 3-mg/ml gatifloxacin (Zymar, Allergan) presoaked collagen shield was associated with lower rates of endophthalmitis if compared with prophylaxis with 5-mg/ml moxifloxacin (Vigamox, Alcon Laboratories) presoaked shields, Brian Haugen, MD, reported.

"Endophthalmitis is a devastating complication following surgery. The Moran Eye Center just published a reported indicating that 27 of 1,525 patients developed endophthalmitis over a 7-year period," Dr. Haugen said.

First the investigators needed to determine the minimal concentration of Sepidermidis that could induce clinical signs of endophthalmitis.

Group 1 of rabbits received 3 mg/ml gatifloxacin drops or the collagen shield soaked in 3 mg/ml gatifloxacin. Group 2 received gatifloxacin drops or a collagen shield soaked in 10 mg/ml of gatifloxacin (Tequin, Bristol-Myers Squibb). Group 3 animals were given 5 mg/ml moxifloxacin drops, or a shield soaked in 5-mg/ml moxifloxacin. Finally, Group 4, the control group, received balanced saline solution (BSS) drops or a shield soaked in BSS. Each eye received one drop of gatifloxacin, moxifloxacin, or BSS four times beginning 1 hour before the bacterial injection. Immediately after the injection, the collagen shield was placed in the eye randomly assigned to receive the shield.

The antibiotic drops were instilled once every 2 hours postoperatively for a total of five doses, according to Dr. Haugen. The animals in the gatifloxacin group received the 3-mg/ml gatifloxacin drops to determine if the collagen shield soaked in a higher concentration of gatifloxacin made a difference in the treatment results.

Signs of endophthalmitis

Twenty-four hours after the bacterial challenge, the animals were examined by slit lamp to determine the presence of the clinical signs of endophthalmitis. The different clinical parameters were scored by a scale ranging from 0 to 4, with 4 representing the presence of the worst clinical signs of endophthalmitis. Then, a total clinical score was noted for each eye.

"The reaction with the antibiotic-soaked shields in place was not as intense as in the control group. There was more cell and flare in the eyes with a moxifloxacin shield," Dr. Haugen stated.

He also reported that the main clinical scores for the shields were not significantly different from those of the topical drops alone.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.